Initial Experience of the Treatment of Kidney Stones With the MONARCH™ Platform, Urology
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Auris Health, Inc.
- Enrollment
- 15
- Locations
- 1
- Primary Endpoint
- Completion of the Robotic Assisted Mini-PCNL Kidney Stone Removal Procedure.
Study Overview
Brief Summary
The purpose of this study is to collect descriptive performance data using the MONARCH Platform, Urology (a novel robotic device) to perform mini-percutaneous nephrolithotomy (kidney stone removal) procedures. Data gathered from this study will be used to optimize the robotic platform and inform training and education material for the future users.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 22 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Simple renal caliceal and/or pyelo stone(s), greater than or equal to (>=) 10 millimeter in size identified on computerized tomography (CT) scan, and appropriate for Percutaneous nephrolithotomy (PCNL) treatment according to American Urological Association (AUA) guidelines
- •Normal upper tract anatomy, amenable to PCNL and ureteroscopy
- •Body mass index less than (<) 40 kilogram-meter squared
- •Participants with a percutaneous tract length <15 centimeter as measured by the estimation of the skin to stone or skin to appropriate calyx for treatment through a CT scan
- •Participant is an appropriate candidate for a mini-PCNL based on the clinical guidelines and investigator assessment
- •Pre-Operative
Exclusion Criteria
- •Any medical or physical condition/limitation that would contraindicate a conventional ureteroscopy or PCNL [for example, atypical interposition of visceral organs (bowel, spleen, or liver)] in the supine position. This assessment will be made by the investigator team
- •Participation in any other clinical trial 30-days before and throughout the duration of the study that might impact the results
- •A solitary functioning kidney
- •Female subjects who are pregnant or nursing or those of childbearing potential refusing a pregnancy test
- •Presence of ureteral impacted stones
- •Presence of ureteral obstruction
- •Presence of untreated urinary tract infection, urosepsis
- •Inability to give consent
- •Presence of a renal mass which has not been investigated
- •Staghorn stone
- •Participant has an electrically or magnetically activated implanted medical device
- •Significant pharmacological anticoagulant therapy or uncorrected bleeding diathesis
- •Tumor in the probable access tract area and potential malignant renal tumor
- •Intra-Procedure Exclusion Criteria:
- •Any presenting condition discovered intra procedurally that in the opinion of the investigator would make participating in this study not in the participant's best interest. For example, participants no longer considered good candidates for a mini-PCNL procedure for the removal of the kidney stones.
Arms & Interventions
Robotic-assisted mini-Percutaneous Nephrolithotomy (PCNL)
Participants with kidney stones will be enrolled for robotic-assisted mini-percutaneous nephrolithotomy procedure using the MONARCH Platform, Urology for removal of kidney stones. The MONARCH Platform, Urology enables electro-mechanical articulation and precise control of a flexible ureteroscope and/or a flexible mini-PCNL suction catheter for visualization and access to the urinary tract for diagnostic and therapeutic procedures.
Intervention: Robotic-assisted mini-PCNL (Device)
Outcomes
Primary Outcomes
Completion of the Robotic Assisted Mini-PCNL Kidney Stone Removal Procedure.
Time Frame: Day of Procedure
Percentage of participants in whom the kidney stone treatment and removal procedure could be successfully completed with the MONARCH™ Platform, Urology.
Secondary Outcomes
No secondary outcomes reported